Silva Rondineli Mendes da, Chaves Gabriela Costa, Chaves Luisa Arueira, Campos Mônica Rodrigues, Luiza Vera Lucia, Bertoldi Andréa Dâmaso, Ross-Degnan Dennis, Emmerick Isabel Cristina Martins
Departamento de Política de Medicamentos e Assistência Farmacêutica, Escola Nacional de Saúde Pública Sergio Arouca, Fiocruz. R. Leopoldo Bulhões 1480, Manguinhos. 21041-210 Rio de Janeiro RJ Brasil.
Faculdade de Farmácia, Universidade Federal do Rio de Janeiro. Macaé RJ Brasil.
Cien Saude Colet. 2017 Aug;22(8):2501-2512. doi: 10.1590/1413-81232017228.01442017.
This paper aims to analyse changes in the retail pharmaceutical market following policy changes in the Farmácia Popular Program (FP), a medicines subsidy program in Brazil. The retrospective longitudinal analyses focus on therapeutic class of agents acting on the renin-angiotensin system. Data obtained from QuintilesIMS (formerly IMS Health) included private retail pharmacy sales volume (pharmaceutical units) and sales values from 2002 to 2013. Analyses evaluated changes in market share following key FP policy changes. The therapeutic class was selected due to its relevance to hypertension treatment. Market share was analysed by therapeutic sub-classes and by individual company. Losartan as a single product accounted for the highest market share among angiotensin II antagonists. National companies had higher sales volume during the study period, while multinational companies had higher sales value. Changes in pharmaceutical market share coincided with the inclusion of specific products in the list of medicines covered by FP and with increases in or exemption from patient copayment.
本文旨在分析巴西药品补贴计划——大众药房计划（FP）政策变化后零售药品市场的变化。回顾性纵向分析聚焦于作用于肾素-血管紧张素系统的药物治疗类别。从昆泰IMS（原IMS健康公司）获得的数据包括2002年至2013年的私立零售药店销售量（药品单位）和销售额。分析评估了FP关键政策变化后市场份额的变化。选择该治疗类别是因其与高血压治疗的相关性。市场份额按治疗亚类和个别公司进行分析。氯沙坦作为单一产品在血管紧张素II拮抗剂中占据最高市场份额。在研究期间，国内公司的销售量较高，而跨国公司的销售额较高。药品市场份额的变化与FP覆盖药品清单中特定产品的纳入以及患者自付费用的增加或豁免相吻合。
